Literature DB >> 8929984

Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice.

I Hassouna1, H Wickert, M Zimmermann, F Gillardon.   

Abstract

Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mammals causes damage to the nigrostriatal pathway similar to that observed in Parkinson's disease. In the present study, we have investigated alterations in cell death effector gene expression induced by the neurotoxin MPTP in mouse substantia nigra. Intraperitoneal MPTP injections in mice resulted in a significant increase in bax mRNA by about two- and three-fold after 3 and 6 days, respectively. The up-regulation of bax mRNA was associated with concomitant increase in Bax immunoreactivity observed mainly in large- and medium-sized neurons in the substantia nigra that are destined to die. Our results indicate a pathophysiological significance of bax, which promotes programmed cell death, in MPTP neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929984     DOI: 10.1016/0304-3940(96)12323-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

1.  Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

Authors:  V Viswanath; Y Wu; R Boonplueang; S Chen; F F Stevenson; F Yantiri; L Yang; M F Beal; J K Andersen
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX.

Authors:  H Ruan; J Wang; L Hu; C S Lin; K R Lamborn; D F Deen
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

5.  Effect of chronic lead exposure on pro-apoptotic Bax and anti-apoptotic Bcl-2 protein expression in rat hippocampus in vivo.

Authors:  Ali M Sharifi; Seyed Hadi Mousavi; Masoumeh Jorjani
Journal:  Cell Mol Neurobiol       Date:  2010-02-11       Impact factor: 5.046

6.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  M Vila; V Jackson-Lewis; S Vukosavic; R Djaldetti; G Liberatore; D Offen; S J Korsmeyer; S Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

7.  Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the Bcl-2/caspase pathways.

Authors:  Hongliang Jiao; Fangxia Guan; Bo Yang; Jianbin Li; Laijun Song; Xiang Hu; Ying Du
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

8.  Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.

Authors:  Marina Yamada; Kotaro Kida; Willington Amutuhaire; Fumito Ichinose; Masao Kaneki
Journal:  Biochem Biophys Res Commun       Date:  2010-10-19       Impact factor: 3.575

Review 9.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells.

Authors:  Dong Wan Kang; Chang Hwa Choi; Ji Yeon Park; Soo Kyung Kang; Yong Keun Kim
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.